🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hyderabad
Clinical trial register · India

Clinical Trials in Hyderabad

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 22 Hyderabad 15 Ahmedabad 12 Pune 12 Bangalore 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Asian Institute of Gastroenterology, India40 AstraZeneca35 Novartis Pharmaceuticals15 Bristol-Myers Squibb15 Eli Lilly and Company14 Clear sponsor filter
Site location
New Delhi22 Hyderabad15 Ahmedabad12 Pune12 Bangalore11
All 45 locations
Target enrolment
to
15 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Gurugram, Mangalore, Kochi, New Delhi, Chandigarh, Vellore, Hyderabad
2025-11-11
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Gurugram, Mangalore, Nashik, New Delhi, Ludhiana, Vellore, Hyderabad, Lucknow
2025-02-07
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Hyderabad, Bangalore, Mumbai, Pune, New Delhi, Bhubaneswar, Chennai, Kolkata
2024-02-28
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
Bangalore, Nagpur, Pune, New Delhi, Hyderabad
2023-10-02
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Hyderabad, Chandigarh, Faridabad, Bengaluru, Trivandrum, Jaipur, Vellore, Lucknow
2023-07-06
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
New Delhi, Madurai, Hyderabad, Lucknow
2022-12-30
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Ahmedabad, Kozhikode, New Delhi, Vellore, Hyderabad, Lucknow, Puducherry
2022-08-10
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Kochi, Pune, New Delhi, Amritsar, Hyderabad, Lucknow, Kolkata
2021-12-13
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Guntur, Hyderabad, Ahmedabad, Vadodara, Belagavi, Manipal, Mysore, Kochi
2021-11-23
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Bangalore, New Delhi, Hyderabad
2021-09-20
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
Novartis Pharmaceuticals
Phase 3
98
New Delhi, Hyderabad, Lucknow, Dehradun
2021-07-28
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Surat, Bangalore, Mumbai, Nashik, New Delhi, Hyderabad
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Kozhikode, Pune, Vellore, Hyderabad, Secunderabad, Kolkata
2020-12-11
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
Novartis Pharmaceuticals
Phase 3
254
Bhubaneswar, Hyderabad
2019-07-26
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Mangalore, Kochi, Mumbai, Pune, New Delhi, Chandigarh, Hyderabad, Howrah
2018-12-28
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/hyderabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.